The Immunotherapy Promise, a collaboration between the Cancer Research Institute (CRI) and Israel Cancer Research Fund (ICRF), will provide funding for qualified scientists at leading universities and research centers throughout Israel with the goal of advancing our understanding of cancer immunotherapy and developing life-extending therapies, novel diagnostic approaches, and/or prevention strategies. This new funding opportunity is aimed at fostering outstanding basic, pre-clinical, and/or translational research in cancer immunology and immunotherapy throughout Israel.
Candidates for The Immunotherapy Promise grants must be Israeli citizens and hold a faculty appointment as a tenure-track assistant professor (or higher rank) at the time of award activation. Research supported by the award must be conducted at medical schools and research centers in Israel. Please note that the CRI/ICRF Immunotherapy Promise Grants do not support research at for-profit institutions.
Together, CRI and ICRF will provide a maximum of four grants at a stipend level of $75,000 per year over two years ($150,000 total) to qualified scientists at leading universities and research centers in Israel. The funds may be used for salary, technical assistance, supplies, capital equipment, or scientific travel. Deductions for administrative overhead or other indirect costs are not allowed from the grant. Payments are made quarterly in U.S. currency to the host institution, earmarked specifically for the principal investigators. Funding for the second year is contingent upon receipt of a satisfactory progress report after the first year.
The Immunotherapy Promise Investigators will be required to attend the annual CRI-CIMT-EATI-AACR International Immunotherapy Conference at least once during the funding period. Expenses related to attendance (registration, travel, hotel accommodations, and meals) will be reimbursed up to $5,000 per meeting, over and above the grant stipend.
All grant proposals will be subject to rigorous peer review by a joint CRI/ICRF scientific review panel (JSRP), but the application and granting processes will be administered by the ICRF. Applications will be considered for funding on the basis of the overall merit of the proposal as determined by the JSRP, relevance of the proposal to the research objectives of the ICRF, CRI and this special program, and the availability of funds.
The Israel Cancer Research Fund will administer the application and grant process. Applications closed January 7, 2019.